From January 1, 2022 to March 13, 2022, the company has repurchased 860,800 shares, representing 0.14% for CNY 9.03 million. With this, the company has completed the repurchase of 5,000,000 shares, representing 0.81% for CNY 59.98 million under the buyback announced on March 15, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.89 CNY | -1.01% | -3.74% | -23.59% |
05-20 | Wanbangde Pharmaceutical Holding Group Co., Ltd. Approves Dividend for the Year 2023 | CI |
05-08 | US FDA Gives Rare Pediatric Disease Drug Designation to Wanbangde Pharmaceutical's Huperzine A | MT |
1st Jan change | Capi. | |
---|---|---|
-23.59% | 417M | |
+16.31% | 42.32B | |
+16.32% | 21.29B | |
+19.33% | 15.29B | |
+18.71% | 14.36B | |
+52.78% | 12.81B | |
-0.05% | 6.79B | |
-12.24% | 6.58B | |
-8.87% | 5.73B | |
+11.64% | 5.51B |
- Stock Market
- Equities
- 002082 Stock
- News Wanbangde Pharmaceutical Holding Group Co., Ltd.
- Tranche Update on Wanbangde Pharmaceutical Holding Group Co., Ltd.'s Equity Buyback Plan announced on March 15, 2021.